XML 62 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
REVENUE AND CREDIT CONCENTRATIONS (Tables) - Net Product Revenue
12 Months Ended
Dec. 31, 2017
Geographic Concentration Risk  
Concentration Risk [Line Items]  
Schedules of Consolidated Net Product Revenue Concentration

The table below summarizes consolidated net product revenue concentrations based on patient location for Brineura, Firdapse, Kuvan, Naglazyme, and Vimizim, which are sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme. Genzyme is the Companys sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.

 

 

 

Years Ended December 31,

 

 

 

2017

 

 

2016

 

 

2015

 

Region:

 

 

 

 

 

 

 

 

 

 

 

 

United States

 

 

39

%

 

 

37

%

 

 

39

%

Europe

 

 

21

%

 

 

23

%

 

 

19

%

Latin America

 

 

14

%

 

 

13

%

 

 

16

%

Rest of world

 

 

19

%

 

 

19

%

 

 

15

%

Total net product revenues marketed by the

   Company

 

 

93

%

 

 

92

%

 

 

89

%

Aldurazyme net product revenues marketed by

   Genzyme

 

 

7

%

 

 

8

%

 

 

11

%

Total net product revenue

 

 

100

%

 

 

100

%

 

 

100

%

 

Customer Concentration Risk  
Concentration Risk [Line Items]  
Schedules of Consolidated Net Product Revenue Concentration

The following table illustrates the percentage of the Company’s consolidated net product revenues attributed to the Company’s largest customers.

 

 

 

For the Years Ended December 31,

 

 

 

2017

 

 

2016

 

 

2015

 

Customer A

 

 

18

%

 

 

19

%

 

 

15

%

Customer B

 

 

14

%

 

 

13

%

 

 

13

%

Customer C

 

 

10

%

 

 

10

%

 

 

 

Customer D

 

 

7

%

 

 

8

%

 

 

11

%

Customer E

 

 

7

%

 

 

6

%

 

 

10

%

Total

 

 

56

%

 

 

56

%

 

 

49

%